Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Honey’s Potential to Save Lives By Destroying Harmful Fungus

By Drug Discovery Trends Editor | February 9, 2016

Source: University of ManchesterThe healing powers of honey have been known for thousands of years. Now a graduate from The University of Manchester has discovered a powerful link between a medicinal type of honey and the destruction of a fungus that can cause blindness or even death.

In the first study of its kind, student Zain Habib Alhindi used different concentrations of Surgihoney, a biologically engineered honey that produces chemically reactive molecules containing oxygen, to test how effective it could be in destroying the fungus Fusarium, which is found on plants and in soil and can cause devastating infections in vulnerable people.

Zain discovered even the lowest concentrations had a significant effect in breaking down the cell wall of the fungus, demonstrating its potential as a future treatment for patients.

She said: “Chronic infections, such as those found in long-lasting wounds comprise about 60-80 per cent of infectious diseases in humans and the way fungi invades wounds is associated with the use of broad-spectrum antibiotics.

“However, we know that biofilms – thin layers of microorganisms, which group together – contribute to the severity and delayed healing of chronic wounds.

“Through my research I wanted to show the potential for honey as a healing agent to break through these biofilms and in doing so increase the process of healing. What I found amazing is that honey actually works better than some antifungals.”

Zain (29) from Saudi Arabia is one of only handful of students who have completed The University’s new master’s degree course in Medical Mycology which runs for just one year instead of the customary two, making it a world first.

Because of the way the course is structured Zain was able to spend almost a third of her time in the lab working on experiments to test her theory under the supervision of Dr Riina Rautemaa-Richardson, Senior Lecturer in Infectious Diseases in The University’s Institute of Inflammation and Repair.

Dr Rautemaa-Richardson believes it’s this intensive, hands-on approach, which appeals to her students and equips them for a career in specialised medicine or research.

She said: “This dynamic course provides a solid foundation to the scientific, practical and clinical aspects of fungal diseases, which allows clinically relevant research like this. In the world of increasing antimicrobial resistance new approaches to the management of infections, sparing the real antibiotics, are highly relevant and important.”

Professor Malcolm Richardson, Professor of Medical Mycology at The University of Manchester added: “Honey has been used since ancient times for the treatment of several diseases. Only a limited number of investigations have looked at its effect on pathogenic fungi.

“This opens an exciting door for further work on the application of honey for many fungal infections and allows researchers to adopt different options for treating a range of superficial infections.”

Source: University of Manchester


Filed Under: Drug Discovery

 

Related Articles Read More >

The FDA’s AI ambitions depend on better data practices
Researchers working in the clinical laboratory
Outpatient clinics are becoming critical Infrastructure for drug trials
SAS launches clinical trial analytics software built on its Viya cloud native analytics platform
Bayer’s Lynkuet approved by FDA for menopausal hot flashes
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE